Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization

Journal of Infectious Diseases

Volumn 194, Issue 3, 2006, Pages 325-330

  Batzloff, Michael R ^a   Hartas, Jon ^a   Zeng, Weiguang ^b   Jackson, David C ^b   Good, Michael F ^a,c  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; EPITOPE; IMMUNOGLOBULIN A; LIPOPEPTIDE; M PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL GROWTH; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; INOCULATION; MOUSE; MYCOPLASMA FERMENTANS; NONHUMAN; OPSONIZATION; OUTBRED STRAIN; PEPTIDE SYNTHESIS; PHAGOCYTOSIS; PHARYNGITIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; THROAT CULTURE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CARRIER PROTEINS; EPITOPES, T-LYMPHOCYTE; FEMALE; GONADOTROPIN-RELEASING HORMONE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIPOPROTEINS; MICE; PHARYNX; PROTEIN CONFORMATION; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES; VACCINES, SUBUNIT;

EID: 33746326837     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/505146     Document Type: Article

References (21)

1. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000; 13:470-511.
2. Hu MC, Walls MA, Stroop SD, Reddish MA, Beall B, Dale JB. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 2002; 70:2171-7.
3. Bessen D, Fischetti VA. Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci. Infect Immun 1988; 56:2666-72.
4. Hayman WA, Brandt ER, Relf WA, Cooper J, Saul A, Good MF. Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. Int Immunol 1997; 9:1723-33.
5. Batzloff MR, Hayman WA, Davies MR, et al. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. J Infect Dis 2003; 187:1598-608.
6. Batzloff M, Yan H, Davies M, Hartas J, Good M. Preclinical evaluation of a vaccine based on conserved region of M protein that prevents group A streptococcal infection. Indian J Med Res 2004; 119(Suppl): 104-7.
7. Brandtzaeg P. Role of secretory antibodies in the defence against infections. Int J Med Microbiol 2003; 293:3-15.
8. Brandt ER, Hayman WA, Currie B, et al. Functional analysis of IgA antibodies specific for a conserved epitope within the M protein of group A streptococci from Australian Aboriginal endemic communities. Int Immunol 1999; 11:569-76.
9. D'Alessandri R, Plotkin G, Kluge RM, et al. Protective studies with group A streptococcal M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization with type 3 or type 12 group A streptococcus. J Infect Dis 1978; 138:712-8.
10. Bessen D, Fischetti VA. Passive acquired mucosal immunity to group A streptococci by secretory immunoglobulin A. J Exp Med 1988; 167: 1945-50.
11. Fujihashi K, Koga T, van Ginkel FW, Hagiwara Y, McGhee JR. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 2002; 20:2431-8.
12. BenMohamed L, Belkaid Y, Loing E, Brahimi K, Gras-Masse H, Druilhe P. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur J Immunol 2002; 32:2274-81.
13. Benmohamed L, Thomas A, Bossus M, et al. High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules. Vaccine 2000; 18: 2843-55.
14. Pialoux G, Gahery-Segard H, Sermet S, et al. Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers. AIDS 2001; 15:1239-49.
15. Jackson DC, Lau YF, Le T, et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci USA 2004; 101:15440-5.
16. Ghosh S, Walker J, Jackson DC. Identification of canine helper T cell epitopes from the fusion protein of canine distemper virus. Immunology 2001; 104:58-66.
17. Zeng W, Ghosh S, Lau YF, Brown LE, Jackson DC. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol 2002; 169:4905-12.
18. Brandt ER, Hayman WA, Currie B, et al. Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci. Immunology 1996; 89:331-7.
19. Johnson DR, Kaplan EL, Sramek J, et al. Laboratory diagnosis of group A streptococcal infections. 1st ed. Geneva: World Health Organization, 1996.
20. Asakura K, Saito H, Hata M, Kataura A. Antigen-specific IgA response of NALT and cervical lymph node cells in antigen-primed rats. Acta Otolaryngol 1998; 118:859-63.
21. Lowell GH, Ballou WR, Smith LF, Wirtz RA, Zollinger WD, Hockmeyer WT. Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides. Science 1988; 240:800-2.